Hormone replacement therapy with estradiol and drospirenone: An overview of the clinical data

  title={Hormone replacement therapy with estradiol and drospirenone: An overview of the clinical data},
  author={Malcolm I. Whitehead},
  journal={Post Reproductive Health},
  pages={4 - 7}
  • M. Whitehead
  • Published 1 March 2006
  • Medicine, Biology
  • Post Reproductive Health
A new form of continuous combined hormone replacement therapy has become available that contains estradiol and drospirenone as the progestogen component. Drospirenone is a synthetic progestogen, the only one in hormone replacement therapy in the UK that possesses clinically relevant anti-mineralocorticoid activity. The combination of estradiol and drospirenone has been shown to provide relief from estrogen-deficiency symptoms of the menopause. It also helps to prevent osteoporosis in… 

Figures and Tables from this paper

Combination of Drospirenone and Estradiol: A New Hormone Therapy in Postmenopausal Women

  • J. Huber
  • Biology, Medicine
    Women's health
  • 2007
The problems that arise in connection with the menopause have been treated for many years with various hormone-replacement therapy formulations. The spironolactone derivative drospirenone is a novel

Drospirenone increases endothelial nitric oxide synthesis via a combined action on progesterone and mineralocorticoid receptors.

The results help to interpret the anti-hypertensive effects of hormonal therapies containing Drospirenone and compare them with those of progesterone (P) and of medroxyprogesterone acetate (MPA).

Not for Sale or Commercial Distribution

An elevated thyroid-stimulating hormone in patients with a normal free thyroxine level reflects the state of subclinical hypothyroidism, and both observation without treatment, or early treatment are reasonable options.

Analysis of correlation between blood biochemical indicators and bone mineral density of post-menopausal women

The purpose of this study was to investigate the significance of sex hormones and some biochemical indicators related to bone metabolism in the genesis and development of osteoporosis and to verify the correlations between the indicators and BMD.

New validated Reverse Phase Ultra Performance Liquid Chromatography method for drospirenone and estetrol in Active Pharmaceutical Ingredient and tablet form and its stress studies

The UPLC technique we have developed is completely unique and reliable and can quantitatively measure drospirenone and estetrol (E4) simultaneously. The chromatographic column of Luna C18 (100 × 2.6

Undertreatment of menopausal symptoms and novel options for comprehensive management

  • V. Lewis
  • Medicine
    Current medical research and opinion
  • 2009
Several new menopausal therapies that may help to address the ongoing unmet need for safe and effective therapies for postmenopausal women are currently in development, including the TSEC, which provides the benefits of both a selective estrogen receptor modulator and conjugated estrogens with an improved tolerability profile.



Drospirenone: a new cardiovascular-active progestin with antialdosterone and antiandrogenic properties.

  • A. Rübig
  • Biology, Medicine
    Climacteric : the journal of the International Menopause Society
  • 2003
Phase III studies with E2/DRSP show that DRSP does not antagonize the well-documented reductions of blood pressure associated with E1; rather, small DRSP dose-related reductions in systolic and diastolic blood pressures were observed, which should be beneficial for recipients, especially those who are mildly hypertensive.

Safety and efficacy of drospirenone used in a continuous combination with 17β-estradiol for prevention of postmenopausal osteoporosis

Although endometrial thickness increased slightly, the safety of the endometrium was assured, as no cases of hyperplasia or cancer occurred, and the combination of 17β-estradiol and drospirenone has a positive effect on BMD and a potentially beneficial effect on lipids.

Long-term safety of drospirenone-estradiol for hormone therapy: a randomized, double-blind, multicenter trial

The use of drospirenone combined with estradiol provides protection against endometrial hyperplasia, reduces endometrian bleeding with time, and relieves menopausal symptoms.

Estradiol and drospirenone for climacteric symptoms in postmenopausal women: a double-blind, randomized, placebo-controlled study of the safety and efficacy of three dose regimens

It is demonstrated that the combinations of 1, 2, and 3’mg drospirenone with 1 mg estradiol are safe and effective for the treatment of climacteric symptoms.

Hormone therapy: the European women's perspective

To a large extent, users are satisfied with their HT and willing to pursue its use for longer periods of time, and the preponderant differences in awareness of benefits and risks in HT users are demonstrated.

New progestogens: a review of their effects in perimenopausal and postmenopausal women

  • Drugs Aging
  • 2004

Angeliq summary of product characteristics . June 2005 2